Table 1.
Clinical diagnosis | Sex | Age | Immunhistochemistry for anterior lobe hormones | Tumor size based on preoperative MRI (mm3) | Ki-67 proliferation index (%) |
---|---|---|---|---|---|
GH producing | F | 43 | GH | – | 1–3 |
GH producing | M | 49 | GH | – | < 1 |
GH producing | M | 51 | GH, PRL | – | < 3 |
GH producing | M | 22 | GH, PRL | 11,571 | 3 |
GH producing | M | 32 | GH, PRL | – | 3–4 |
GH producing | F | 49 | GH, PRL | 2652 | 3–4 |
GH producing | F | 22 | GH, PRL | – | 4–5 |
GH producing | M | 35 | GH, PRL | – | 6 |
GH producing | M | 30 | GH, PRL | 4840.495 | 8 |
GH producing | F | 48 | GH, PRL | – | 10 |
GH producing | F | 35 | GH, PRL | – | 5–6 |
GH producing | F | 60 | GH, PRL | – | < 3 |
NFPA | F | 39 | FSH | – | 1–2 |
NFPA | M | 51 | FSH | 15,488 | 2–3 |
NFPA | M | 44 | FSH | – | 2–3 |
NFPA | F | 76 | FSH | 3825 | 2–3 |
NFPA | M | 38 | FSH | – | 3–4 |
NFPA | F | 72 | FSH, LH | – | 1–2 |
NFPA | M | 63 | FSH, LH | 41,055 | < 1 |
NFPA | F | 49 | FSH, LH | 3744 | < 1 |
NFPA | M | 62 | FSH, LH | – | < 3 |
NFPA | M | 67 | FSH, LH | – | 3–4 |
NFPA | M | 43 | FSH, LH | – | 7–10 |
NFPA | M | 64 | FSH, LH | 126,000 | < 3 |
NFPA | F | 74 | FSH, LH | – | < 3 |
NFPA | F | 73 | FSH, LH | 12,000 | < 2 |
NFPA | F | 68 | FSH, LH | – | 3–4 |
NFPA | M | 73 | FSH, LH | – | 2–3 |
NFPA | F | 80 | FSH, LH | 19,600 | 2–3 |
NFPA | F | 69 | FSH, LH | 20,240 | < 3 |
NFPA | M | 38 | FSH, LH | – | 3–4 |
NFPA | F | 37 | FSH, LH | 1872 | 7–8 |
NFPA | M | 73 | LH | 13,500 | 2 |
NFPA | M | 72 | LH | 4590 | < 2 |
NFPA | F | 43 | Negative | 4987.5 | 1 |
NFPA | F | 50 | Negative | – | 2 |
NFPA | F | 64 | Negative | – | 1 |
NFPA | F | 58 | Negative | 3570 | 4 |
NFPA | M | 73 | Negative | 12,144 | 3–4 |
NFPA | F | 64 | Negative | – | 5 |
NFPA | M | 58 | Negative | 35,640 | 5–7 |
NFPA | M | 50 | Negative | – | < 2 |
NFPA | F | 49 | Negative | – | 3–4 |
NFPA | F | 65 | Negative | 2523.312 | 3–4 |
NFPA | F | 60 | Negative | – | 5 |